01.02.2026
A revised list of variations according to Articles 21-24 TPO comes into force on 1 February 2026
01.02.2026
The Guidance document Drug Safety Signals HMP has been comprehensively revised, its structure has been modified and its content has been clarified; in parallel, the Signal Notification Form has been revised and adapted to the new requirements
01.02.2026
The information sheets on specimen texts for medicinal product information for paracetamol, acetylsalicylic acid and NSAIDs are to be archived
30.01.2026
from recipe book to mandatory quality standard
30.01.2026
Results of a Swissmedic focus campaign of importers
30.01.2026
GPI version 2.0 have been updated to Version 2.1. This revision clearly reflects the requirements set out in Art. 71 para. 2 MedDO and Art. 64 para. 2 IvDO. Details can be found in the document's change history.
29.01.2026
Extension of therapeutic indication (02)
28.01.2026
Leberschädigung mit Ocrelizumab
27.01.2026
Extension of therapeutic indication (01)
23.01.2026
Ernsthafter Qualitätsmangel im Zusammenhang mit der Nadel der vorgefüllten Spritze
22.01.2026
Rückzug der Chargen 4400869, 4400443, 4400446 und 4401766 bis auf Stufe Detailhandel
21.01.2026
Requirements regarding a Notified Body Opinion
19.01.2026
Extension of therapeutic indication (01)
15.01.2026
Extension of therapeutic indication (01)
15.01.2026
Agreement will permit socially acceptable implementation of staff reduction
13.01.2026
New blood donation criteria from Swiss Transfusion SRC effective 1 February 2026
13.01.2026
Befristete Bewilligung zum Vertrieb in deutscher Aufmachung
12.01.2026
On 28 May 2026, Swissmedic is hosting a free online training on how to register medical devices in swissdamed
12.01.2026
On 12 January 2026, Vincenza Trivigno will take up her post as Executive Director of Swissmedic
08.01.2026
Rückzug der Chargen PG21CH2507 und PG21CH2508 / Bulk Batch ID: F0392504 bis auf Stufe Detailhandel (Klinik / Spital)
08.01.2026
Befristete Bewilligung zum Vertrieb in irischer, schwedischer und finnischer Aufmachung
07.01.2026
A forum for the targeted clarification of project-specific GMP and GDP issues with Swissmedic
07.01.2026
Latest edition
06.01.2026
Job advertisement | Division Operational Support Services
06.01.2026
Learning from adverse reaction reports – cases from pharmacovigilance
06.01.2026
Befristete Bewilligung zum Vertrieb in taiwanesischer Aufmachung
06.01.2026
A revised list of variations according to Articles 21-24 TPO comes into force on 1 February 2026
01.01.2026
Der Institutsrat hat die Fassung 12.1 der Europäischen Pharmakopöe auf den 1. Januar 2026 in Kraft gesetzt
01.01.2026
With effect from 1 January 2026, it will be possible to dispense with a paper copy of the package leaflet for certain veterinary medicinal products.
30.12.2025
Befristete Bewilligung zum Vertrieb in deutscher Aufmachung
29.12.2025
Extension of therapeutic indication (01)
23.12.2025
Rückzug der Chargen 239415, 239425, 239240, 239187, 239208, 239287, 239283 bis auf Stufe Detailhandel
23.12.2025
Rückzug der Charge 253527651 bis auf Stufe Detailhandel
23.12.2025
Extension of therapeutic indication (01)
23.12.2025
The registration of devices, systems, and procedure packs will become mandatory in swissdamed as of July 1, 2026, with a transition period until December 31, 2026
22.12.2025
Deadline of 12 April 2026 for comments
Permanent link of this page
www.swissmedic.ch/updates-en
News channel of this page
